- Home
- QNCX vs MCRB Comparison
QNCX vs MCRB Comparison
Compare QNCX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | MCRB |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 162.7M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | QNCX | MCRB |
|---|---|---|
| Price | $2.81 | $15.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | $7.67 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 698.3K | 73.2K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $24.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $6.53 |
| 52 Week High | $4.55 | $29.98 |
Technical Indicators
Market Signals| Indicator | QNCX | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 46.33 |
| Support Level | $3.18 | $14.50 |
| Resistance Level | $3.38 | $15.41 |
| Average True Range (ATR) | 0.27 | 0.82 |
| MACD | -0.17 | 0.06 |
| Stochastic Oscillator | 6.51 | 53.15 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.